Corneal endothelial cell loss after EX-PRESS surgery depends on site of insertion, cornea or trabecular meshwork

doi:10.21203/rs.3.rs-2185446/v1

Download PDF

Research Article

Corneal endothelial cell loss after EX-PRESS surgery depends on site of insertion, cornea or trabecular meshwork

https://doi.org/10.21203/rs.3.rs-2185446/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 05 Jun, 2023

Read the published version in International Ophthalmology →

You are reading this latest preprint version

Purpose

Previously, we reported that the Ex-press® shunt (EXP) was associated with more rapid reduction of corneal endothelial cells when inserted into the cornea rather than the trabecular meshwork (TM). We compared the reduction rate of corneal endothelial cells between the corneal insertion group and TM insertion group.

Methods

This was a retrospective study. We included patients who had undergone EXP surgery and were followed for > 5 years. We analyzed the corneal endothelial cell density (ECD) before and after EXP implantation.

Results

We included 25 patients in the corneal insertion group and 53 patients in the TM insertion group. One patient in the corneal insertion group developed bullous keratopathy. The ECD decreased significantly more rapidly in the corneal insertion group (p < 0.0001), in whom the mean ECD decreased from 2227 ± 443 to 1415 ± 573 cells/mm² at 5 years with a mean 5-year survival rate of 64.9 ± 21.9%. By contrast, in the TM insertion group, the mean ECD decreased from 2356 ± 364 to 2124 ± 579 cells/mm² at 5 years, and the mean 5-year survival rate was 89.3 ± 18.0%. The decrease rate of ECD was calculated as 8.3%/year in the corneal insertion group and 2.2%/year in the TM insertion group.

Conclusions

Insertion into cornea is a risk factor for rapid ECD loss. The EXP should be inserted into the TM to preserve the corneal endothelial cells.

Ex-Press

glaucoma

corneal endothelial cells

factors

Filtration surgery using an Ex-Press® shunt (EXP; Alcon Laboratories, Fort Worth, TX, USA) is performed worldwide and was approved in Japan in December 2011. This surgery is performed to reduce intraocular pressure (IOP) for glaucoma patients. EXP is a stainless-steel filtration device designed to shunt the aqueous humor from the anterior chamber to the subconjunctival space. This surgery is performed to reduce intraocular pressure (IOP) for glaucoma patients. EXP surgery is expected to be a minimally invasive surgery to replace trabeculectomy (Trab), and many complication studies of surgical outcomes between EXP and Trab have been reported. Across several studies, the surgical outcomes of EXP were similar to those of Trab [1–5]. As a feature of EXP surgery, it is not necessary to remove the trabecular meshwork or resect the peripheral iris. For these reasons, the risk of vitreous hemorrhage and vitreous prolapse is low. There are several reports showing that postoperative complications are fewer with EXP than with Trab [1, 4]. In addition, it has also been reported that postoperative astigmatism is less prevalent and visual acuity recovers more quickly with EXP [6, 7]. There are also reports that EXP results in lower corneal endothelial cell loss from inflammation [8]. However, there have been reports that EXP surgery led to a rapid decrease in corneal endothelial cells [9, 10]. In fact, we experienced a case who developed bullous keratopathy after EXP [11].

Bullous keratopathy due to corneal endothelial cell reduction is one of the serious complications of filtration surgery. The corneal endothelial cells work to maintain corneal transparency [12]. Some previous studies have reported that Trab reduced corneal endothelial cell density (ECD) from 2.2 to 9.3% after two years [10, 13]. There are several reports of corneal endothelial cell loss after EXP surgery [8–10, 14, 15], but these previous reports have shown large differences in the reduction ratio of ECD. The factors that reduce ECD are not known in detail. We previously investigated the factors affecting reduction of corneal endothelial cells after EXP [15] and found that insertion of EXP into the cornea causes a faster decrease than insertion into the trabecular meshwork (TM).

We followed patients who underwent EXP surgery for more than 5 years and measured the density of their corneal endothelial cells. There has been no previous report with long-term data of ECD loss after EXP. We compared the reduction rates of ECD for the corneal insertion group and TM insertion group.

Patients

This was a retrospective single-facility study. We included consecutive glaucoma patients who underwent EXP surgery for the first time at Toyama University Hospital and were followed for > 5 years. EXP is contraindicated for use in patients with uveitis or primary angle closure glaucoma because these diseases pose a risk of EXP obstruction due to the transformation of peripheral anterior synechia. As a result, we performed EXP surgery for patients with primary open-angle glaucoma (POAG) or pseudo-exfoliation glaucoma (PEXG). In patients who underwent binocular surgery, we used unilateral data from the eye that was operated on first. We excluded patients who had a history of conventional trabeculectomy, laser iridotomy, peripheral iridotomy, long tube shunt surgery or keratoplasty. We excluded who had corneal disease as corneal dystrophy. We included patients with a history of cataract surgery, trabeculotomy (TLO) (including the Trabectome® procedure, a canaloplasty) or vitrectomy. Finally, we recruited 78 eyes to the study.

All subjects were recruited during the period from September 2012 to March 2017. All patients underwent a comprehensive ophthalmic examination including refraction (KR-800PA; Topcom, Tokyo), Goldmann gonioscopy (AU-910-4(O4GFA); Ocular; Washington, USA), Goldmann applanation tonometry (GAT) (AT900; HAGG; Bern, Switzerland), a fundus examination, automated perimetry (Humphrey Field Analyzer; Carl Zeiss Meditec, Dublin, CA), measurement with optical coherent tomography (OCT) RS-3000 (Nidek; Aichi, Japan) and measurement of the central corneal thickness (CCT) with AS-OCT (CASIA SS-1000; Tomey, Nagoya, Japan). Orthoptists helped these exams. We confirmed the diagnosis of glaucoma from these test results. The IOP was measured using GAT. The patients were already taking glaucoma medications, if tolerated, but required further treatment to lower their IOP due to the progression of their visual field disorder. This study is retrospective and did not use specific surgical criteria for glaucoma and cataracts. Surgical indications were decided by the judgment of one glaucoma specialist (N.T). The preoperative (baseline) IOP was defined as the mean of two measurements with Goldmann applanation tonometry (GAT) at the patient's visits immediately before surgery.

The research protocol was approved by the Institutional Review Board of the University of Toyama, and the procedures used conformed to the tenets of the Declaration of Helsinki. After the nature and possible consequences of the study were explained to the patients, written informed consent was obtained from all participants in the study.

Surgical techniques

All operated were performed by one surgeon (N.T.). The surgeon in this study has abundant experience of EXP surgery. Retrobulbar anesthesia was administered. A standard fornix-based conjunctival incision was made to gain access to the scleral bed adjacent to the limbus. A single 3.5x3.5mm square scleral flap was created at superior nasal or superior temporal. Mitomycin C (MMC) solution (0.04 mg/ml) was applied below the conjunctiva and below the scleral flap for 4 min. At this point, the eye was a completely enclosed space, and thus the MMC solution could not flow into the anterior chamber. The treated area was then irrigated with approx. 100 ml of balanced salt solution. If the patient required simultaneous cataract surgery, the cataract surgery was performed at this time. Phacoemulsification was performed with a WhiteStar Signature system (Abbott Medical Optics, Santa Ana, CA), and the intraocular lens (IOL) was implanted from a clear temporal cornea. Since this was a retrospective study, no clear criteria for surgery were established such as VA or Emery grades or age; rather, cataract surgery was performed according to the judgment of the operator.

The scleral flap was lifted, and a 25-ga. needle was horizontally inserted into the anterior chamber at the surgical limbus from the sclera-cornea transition zone parallel with the iris to create a path for the EXP (model P50). The EXP shunt was then inserted into the anterior chamber. We did not use gonioscopy intraoperatively. The scleral flap was sutured using 10 − 0 nylon, and the tension on the sutures was adjusted to maintain the anterior chamber depth with a slow flow of aqueous humor around the margins of the scleral flap. Most of the cases received 2 sutures. The conjunctiva was meticulously closed with 10 − 0 nylon sutures. We confirmed that there was no leakage from the blebs.

Postoperative treatment

The postoperative treatment protocol was the same in both groups. The postoperative treatments consisted of topical steroids, antibiotics, and non-steroidal anti-inflammatory drugs (NSAIDs). The antibiotics were applied for 4–6 weeks. The steroid and NSAID doses were reduced over the 12-week period after the intervention. After surgery, glaucoma medications were stopped in all cases. Glaucoma medications were later added back at the discretion of the physicians. We counted a compounded agent as two medications. We performed laser suture-lysis or needling when the operator determined that these treatments were necessary.

Grouping

We characterized the insertion position of EXP as corneal insertion or TM insertion, and divided subjects into two groups accordingly. We defined a case as TM insertion if any part of the EXP touched the TM (Fig. 1); and defined the remainder as corneal insertion. We confirmed the insertion position of the EXP with a Gonio angle mirror at 3 months after surgery.

Evaluation of reduction rate of ECD

We examined the ECD with an EM-4000 specular microscope (Tomey Corp., Nagoya, Japan) that could calculate the value of the density automatically. We measured ECD every 6 months after surgery. The values were measured just once before surgery and once after, and do not represent an average of multiple measurements. We measured only the central ECD. We defined the reduction rate of ECD as the ratio of post-operative ECD from pre-operative ECD. We excluded the data of patients who underwent additional surgery after EXP.

Statistical analysis

We used a paired t-test and Fisher's exact test for comparisons between two groups. We used a Wilcoxon signed-rank test to compare pre-operative and post-operative IOP, glaucoma medication and ECD. We used JMP Pro 14 software (SAS, Cary, NC) for all statistical analyses. Significance was defined as a p-value < 0.05.

Ophthalmic data

The surgeries were conducted without intraoperative complications such as expulsive hemorrhage. There were two cases who could not be inserted EXP. These two cases underwent conventional trabeculectomy. These cases were excluded from this study. Finally, we analyzed 78 eyes. Table 1 shows the analyzed ophthalmic data: patient age, central corneal thickness (CCT), insertion position (cornea insertion/TM insertion), history of TLO (Yes/No), type of glaucoma (POAG/PEXG) and surgical method (EXP surgery alone/simultaneous cataract surgery). There was no case in which the EXP was inserted into the ciliary body. There were no factors significantly different. Post-operative IOPs are summarized in Table 2. Post-operative IOP was significantly decreased (p < 0.0001) at any point of the period. The number of postoperative glaucoma medications is summarized in Table 3.

Table 1

Demographic and Clinical Data of Study Participants
Factors	Corneal insertion group (26 eyes)	TM insertion group (53 eyes)	p value
Gender (male/female)	11/15	25/28	0.530
Age; ys	69.7 ± 10.1	68.1 ± 11.3	0.546
Right/Left	14/12	22/31	0.301
CCT; mm	523 ± 43	523 ± 43	0.810
ECD; cells/mm²	2227 ± 443	2356 ± 364	0.194
Type of glaucoma (POAG/PEXG)	20/15	29/24	0.225
History of TLO (y/n)	6/20	13/40	0.960
Surgical method (Single/ Triple)	19/7	30/22	0.118
CCT: Central corneal thickness, TM: Trabecular meshwork ECD: endothelial cells density, TLO: Trabeculotomy, POAG: primary open angle glaucoma, PEXG: pseudo-exfoliation glaucoma, Single: Ex-press surgery alone, Triple: Simultaneous cataract surgery

Table 2

Post-operative IOP
mmHg	Corneal insertion group	TM insertion group	p value
Pre-operative	24.4 ± 10.1	23.7 ± 8.6	0.774
1 year	11.2 ± 3.9	10.9 ± 3.6	0.746
2yrs	11.5 ± 3.7	10.2 ± 3.7	0.133
3yrs	11.2 ± 3.7	10.8 ± 3.8	0.615
4yrs	12.2 ± 4.1	10.9 ± 4.0	0.186
5yrs	11.3 ± 4.0	11.4 ± 4.3	0.952
TM: trabecular meshwork

Table 3

The number of post-operative glaucoma medications
	Corneal insertion group	TM insertion group	p value
Pre-operative	4.1 ± 0.5	3.9 ± 0.7	0.142
1 year	1.5 ± 1.7	0.7 ± 1.3	0.900
2yrs	2.2 ± 1.8	1.3 ± 1.6	0.138
3yrs	2.5 ± 1.6	1.9 ± 1.5	0.105
4yrs	2.4 ± 1.6	2.3 ± 1.6	0.692
5yrs	2.7 ± 1.6	2.3 ± 1.7	0.338
TM: trabecular meshwork

Evaluation of ECD

One case of the corneal insertion group developed bullous keratopathy. After 1 year, the ECD in that eye could not be measured. The results of the mean ECD values are shown in Table 4. The mean ECD gradually decreased and showed a significantly greater decrease in the corneal insertion group than the TM group at all points of the follow-up period (p < 0.0001). The mean survival ratios of the ECD values are shown in Table 5. The mean survival ratio was significantly lower in the corneal insertion group at all points of the follow-up period (p < 0.0001). The decrease rate of ECD was calculated as 8.3%/year in the corneal insertion group and 2.2%/year in the TM insertion group.

Table 4

The mean postoperative ECD
Cells/mm²	Corneal insertion group	TM insertion group	p value
Pre-operative	2227 ± 443	2356 ± 364	0.194
1 year	1960 ± 536	2288 ± 442	0.0056
2yrs	1844 ± 549	2256 ± 473	0.0012
3yrs	1681 ± 625	2224 ± 469	< 0.0001
4yrs	1599 ± 554	2218 ± 477	< 0.0001
5yrs	1415 ± 573	2124 ± 579	< 0.0001
ECD: endothelial cells density, TM: trabecular meshwork

Table 5

The mean survival rate of ECD
%	Cornea insertion group	TM insertion group	p value
1 year	91.1 ± 16.7	97.3 ± 11.6	0.0328
2 years	84.9 ± 15.9	95.8 ± 12.2	0.0018
3 years	76.9 ± 20.9	94.8 ± 13.0	< 0.0001
4 years	73.9 ± 19.3	94.0 ± 12.4	< 0.0001
5 years	64.7 ± 21.9	89.3 ± 18.0	< 0.0001
ECD: endothelial cells density, TM: trabecular meshwork

In this study, we excluded patients who underwent additional glaucoma surgery. In other words, the IOP data only pertained to cases with good postoperative IOP that did not require additional glaucoma surgery. On average, EXP decreased the IOP from 23.9 to 11.4 mmHg. The cornea insertion group showed a faster ECD loss than the TM insertion group. In our study, EXP surgery with corneal insertion showed an ECD decrease of 35.3% after 5 years, while that with TM insertion showed a 10.7% decrease.

Arimura et al reported that the mean ECD decrease at 24 months was 18.0% [10]. On the other hand, Ishida et al. reported a mean ECD decrease at 24 months of 4.0% [9]. Omatsu et al. reported that Ex-Press® surgery decreased the mean ECD from 2377 to 2317 after 2 years [8], only 2.5%. In short, the results of previous studies have been very different. One reason for the large variations among these studies might be the differences in the insertion position of the EXP. In our study, the decrease was 15.1% in the corneal insertion group and 4.2% in the TM insertion group. Aoyama et al reported that EXP decreased ECD by 1.8%/year after 3 years [14]. Our 5-year result was 2.2%/year in the TM insertion group.

This study does not compare ECD loss between EXP and Trab. Arimura et al. reported that Trab decreased the ECD by 2.2% [10]. Higashide et al. reported that Trab decreased ECD by 4.8% in case of POAG and 18.2% in the case of PEXG [13]. PEXG has been shown to be a factor of rapid ECD loss [16]. We included PEXG patients in our study. The mean ECD survival ratios of POAG and PEXG after 5 years were 84.5 ± 27.3% and 79.1 ± 22.4%; the difference was not significant (p = 0.292). In TM insertion, our result after 2 years was 4.2%. This result seemed comparable to Trab. Li et al reported that minimally invasive surgery causes less inflammation and had less effect in ECD [17]. EXP surgery is a minimally invasive glaucoma surgery and might have less effect on ECD loss than Trab.

Soro-Martínez et al. reported that Trab simultaneous cataract surgery causes more ECD loss than Trab alone [18]. In this study, the mean ECD survival ratio of EXP alone and EXP and simultaneous cataract surgery after 5 years were 80.1 ± 21.6% and 84.1 ± 23.7%, respectively, with no significant difference (p = 0.460). Kasahara et al. reported that Trabectome® surgery decreased ECD by 2.4% after one year [19]. The mean 5-year ECD survival ratios for groups with and without a history of TLO were 79.8 ± 20.5% and 80.1 ± 22.9%, respectively, with no significant difference (p = 0.292).

The reason that corneal insertion of EXP resulted in faster ECD loss was not clear. Dahlan et al. reported that the presence of a foreign body in the cornea caused rapid ECD loss [20]. Alfawaz et al. reported that anterior segment inflammation adversely affects the ECD [21]. As a foreign body, EXP might cause chronic inflammation and rapid ECD loss [22]. The mechanisms of ECD reduction after EXP surgery might be multifactorial. Other possible mechanisms include abnormal outflow [23].

Our study has some limitations. This is a retrospective single-facility study. We included patients who had undergone cataract surgery and TLO, surgeries associated with ECD loss [19, 24]. The measurement site of the ECD at the central cornea was not identical in all cases, and the value of the ECD might be different for each measurement. We measured the ECD only once at the central cornea. It would have been better to take several measurements and use the average value of ECD. We did not measure the distance from the limbs or the insertion angle of the EXP. These factors might affect the ECD loss. There are many factors for effect to ECD, as the effect of glaucoma medications (carbonic anhydrase inhibitor), peripheral anterior synechia, depth of anterior chamber and phaco-power. We did not consider these factors. Finally, the number of patients was limited.

In conclusion, insertion of EXP into the cornea was a risk factor for rapid corneal endothelial cell loss. If the EXP is inserted into the cornea, it is difficult to reinsert it into the TM. Thus, surgeons need to be very careful regarding the position of the insertion.

Funding statement: The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Employment: No employment by any organization that may gain or lose financially through publication of this manuscript

Financial interests: The authors have no relevant financial or non-financial interests to disclose.

Competing interests: The authors have no relevant financial or non-financial interests to disclose.

Author Contributions: All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Mitsuya Otsuka and Naoki Tojo. The first draft of the manuscript was written by Mitsuya Otsuka and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Ethical approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Toyama University.

Consent to participate: Informed consent was obtained from all individual participants included in the study.

Content and publish: Our manuscript do not contain any individual person’s data in any form.

Arimura S, Takihara Y, Miyake S, Iwasaki K, Gozawa M, Matsumura T, et al. Randomized Clinical Trial for Early Postoperative Complications of Ex-PRESS Implantation versus Trabeculectomy: Complications Postoperatively of Ex-PRESS versus Trabeculectomy Study (CPETS). Scientific reports. 2016;6:26080.
Chen G, Li W, Jiang F, Mao S, Tong Y. Ex-PRESS implantation versus trabeculectomy in open-angle glaucoma: a meta-analysis of randomized controlled clinical trials. PloS one. 2014;9:e86045.
Gonzalez-Rodriguez JM, Trope GE, Drori-Wagschal L, Jinapriya D, Buys YM. Comparison of trabeculectomy versus Ex-PRESS: 3-year follow-up. The British journal of ophthalmology. 2016;100:1269-73.
Netland PA, Sarkisian SR, Jr., Moster MR, Ahmed, II, Condon G, Salim S, et al. Randomized, prospective, comparative trial of EX-PRESS glaucoma filtration device versus trabeculectomy (XVT study). American journal of ophthalmology. 2014;157:433-40 e3.
de Jong LA. The Ex-PRESS glaucoma shunt versus trabeculectomy in open-angle glaucoma: a prospective randomized study. Advances in therapy. 2009;26:336-45.
Beltran-Agullo L, Trope GE, Jin Y, Wagschal LD, Jinapriya D, Buys YM. Comparison of visual recovery following ex-PRESS versus trabeculectomy: results of a prospective randomized controlled trial. Journal of glaucoma. 2015;24:181-6.
Delbeke H, Stalmans I, Vandewalle E, Zeyen T. The Effect of Trabeculectomy on Astigmatism. Journal of glaucoma. 2016;25:e308-12.
Omatsu S, Hirooka K, Nitta E, Ukegawa K. Changes in corneal endothelial cells after trabeculectomy and EX-PRESS shunt: 2-year follow-up. BMC ophthalmology. 2018;18:243.
Ishida K, Moroto N, Murata K, Yamamoto T. Effect of glaucoma implant surgery on intraocular pressure reduction, flare count, anterior chamber depth, and corneal endothelium in primary open-angle glaucoma. Japanese journal of ophthalmology. 2017;61:334-46.
Arimura S, Miyake S, Iwasaki K, Gozawa M, Matsumura T, Takamura Y, et al. Randomised Clinical Trial for Postoperative Complications after Ex-PRESS Implantation versus Trabeculectomy with 2-Year Follow-Up. Scientific reports. 2018;8:16168.
Tojo N, Hayashi A, Miyakoshi A. Corneal decompensation following filtering surgery with the Ex-PRESS((R)) mini glaucoma shunt device. Clinical ophthalmology. 2015;9:499-502.
Mishima S. Clinical investigations on the corneal endothelium. Ophthalmology. 1982;89:525-30.
Higashide T, Nishino T, Sakaguchi K, Yamada Y, Sugiyama K. Determinants of Corneal Endothelial Cell Loss After Trabeculectomy With Mitomycin C. Journal of glaucoma. 2019;28:61-7.
Aoyama Y, Sakata R, Fujishiro T, Honjo M, Shirato S, Aihara M. Changes in corneal endothelial cell density after initial Ex-PRESS drainage device implantation and its relating factors over 3 years. Eye. 2022.
Tojo N, Numata A, Hayashi A. Factors influencing the reduction in corneal endothelial cells after Ex-Press((R)) surgery. International ophthalmology. 2020;40:1201-8.
Hasegawa Y, Nejima R, Mori Y, Sakisaka T, Minami K, Miyata K, et al. Risk factors for corneal endothelial cell loss by cataract surgery in eyes with pseudoexfoliation syndrome. Clinical ophthalmology. 2016;10:1685-9.
Li H, Fang H. Effect of microincisional cataract surgery on inflammatory indicators in tears and corneal endothelial cells in cataract patients. American journal of translational research. 2021;13:7705-14.
Soro-Martinez MI, Villegas-Perez MP, Sobrado-Calvo P, Ruiz-Gomez JM, Miralles de Imperial Mora-Figueroa J. Corneal endothelial cell loss after trabeculectomy or after phacoemulsification, IOL implantation and trabeculectomy in 1 or 2 steps. Graefe's archive for clinical and experimental ophthalmology. 2010;248:249-56.
Kasahara M, Shoji N, Matsumura K. The Influence of Trabectome Surgery on Corneal Endothelial Cells. Journal of glaucoma. 2019;28:150-3.
Dahlan F, Milam DF, Jr., Bunt-Milam AH. Long-term corneal retention of a plant foreign body. Cornea. 1989;8:72-4.
Alfawaz AM, Holland GN, Yu F, Margolis MS, Giaconi JA, Aldave AJ. Corneal Endothelium in Patients with Anterior Uveitis. Ophthalmology. 2016;123:1637-45.
Sagoo P, Chan G, Larkin DF, George AJ. Inflammatory cytokines induce apoptosis of corneal endothelium through nitric oxide. Investigative ophthalmology & visual science. 2004;45:3964-73.
Yamamoto Y, Uno T, Shisida K, Xue L, Shiraishi A, Zheng X, et al. Demonstration of aqueous streaming through a laser iridotomy window against the corneal endothelium. Archives of ophthalmology. 2006;124:387-93.
Bourne RR, Minassian DC, Dart JK, Rosen P, Kaushal S, Wingate N. Effect of cataract surgery on the corneal endothelium: modern phacoemulsification compared with extracapsular cataract surgery. Ophthalmology. 2004;111:679-85.

No competing interests reported.

Download PDF

Journal Publication

published 05 Jun, 2023

Read the published version in International Ophthalmology →

Editorial decision: Major revision
27 Mar, 2023
Reviews received at journal
30 Jan, 2023
Reviewers agreed at journal
17 Jan, 2023
Reviewers invited by journal
12 Nov, 2022
Editor assigned by journal
21 Oct, 2022
Submission checks completed at journal
20 Oct, 2022
First submitted to journal
20 Oct, 2022

You are reading this latest preprint version

Corneal endothelial cell loss after EX-PRESS surgery depends on site of insertion, cornea or trabecular meshwork

Status:

Journal Publication

Version 1

Abstract

Purpose

Methods

Results

Conclusions

Figures

Introduction

Patients And Methods

Patients

Surgical techniques

Postoperative treatment

Grouping

Evaluation of reduction rate of ECD

Statistical analysis

Results

Ophthalmic data

Evaluation of ECD

Discussion

Declarations

References

Additional Declarations

Status:

Journal Publication

Version 1